ARS Pharmaceuticals Stock Rating Upgraded by Zacks Research

Analysts change rating from 'strong sell' to 'hold' for the biopharmaceutical company.

Feb. 27, 2026 at 2:35pm

Got story updates? Submit your updates here. ›

Equity researchers at Zacks Research have upgraded their rating for ARS Pharmaceuticals (NASDAQ:SPRY) from 'strong sell' to 'hold' in a new report. The company is developing a needle-free, low-dose intranasal epinephrine nasal spray for emergency treatment of severe allergic reactions.

Why it matters

The rating upgrade could signal a shift in investor sentiment around ARS Pharmaceuticals and its lead product candidate. As the company works to bring its innovative allergy treatment to market, this change in analyst outlook may impact the stock price and investor confidence.

The details

Zacks Research cited the company's progress in developing its epinephrine nasal spray as the reason for the rating upgrade from 'strong sell' to 'hold'. Other analysts have a mix of ratings, with three 'buy' recommendations, one 'hold', and one 'sell' on the stock. Large institutional investors have also been increasing their stakes in ARS Pharmaceuticals in recent quarters.

  • The rating upgrade was issued on Wednesday, February 27, 2026.

The players

Zacks Research

An equity research firm that provides investment research and analysis.

ARS Pharmaceuticals, Inc.

A biopharmaceutical company developing treatments for severe allergic reactions, including a needle-free intranasal epinephrine spray.

Got photos? Submit your photos here. ›

What’s next

Investors will be watching to see if the rating upgrade leads to increased interest and investment in ARS Pharmaceuticals as the company continues to advance its lead product candidate.

The takeaway

The rating upgrade from Zacks Research reflects growing optimism around ARS Pharmaceuticals and its innovative approach to addressing severe allergic reactions. As the company works to bring its needle-free epinephrine spray to market, this change in analyst sentiment could signal a turning point for the stock.